Skip to Content

Sourcing Stem Cells

Biotech: Could new research end the embryo debate?
January 1, 2001

Ever since human embryonic stem (ES) cells were first isolated in 1998, a debate over their use has raged. Proponents of ES cell research say that the promise of the cells in treating diseases ranging from heart failure to paralysis is invaluable. Critics, on the other hand, argue that the ethical cost of using ES cells, which are derived from human embryos, is too high. Scotland-based PPL Therapeutics hopes to end the debate once and for all by developing an unlimited source of stem cells-without ever creating or destroying an embryo.

The potential of ES cells to treat a spectrum of diseases lies in the fact that the cells are “pluripotent,” meaning they can form any tissue in the adult body. In October, PPL’s labs in Blacksburg, Va., won a $1.9 million grant from the National Institute of Standards and Technology (NIST) for research on reprogramming adult cells to be pluripotent. If PPL succeeds, it will free researchers and eventually doctors from their reliance on a relatively rare commodity: aborted fetuses and embryos left over from in vitro fertilization. “The benefits are ethical on the one hand, and they could be practical on the other,” says Ron James, PPL’s chief executive.

PPL’s three-year grant from NIST allows the company to work only with cells from livestock and nonhuman primates. But if the initial research goes well, the company could privately fund efforts toward its ultimate goal: human-derived cells that can be used in a number of therapeutic applications.

When it comes to explaining just how they plan on reprogramming adult cells to behave like ES cells, PPL executives are understandably tight-lipped–after all, such a trick is the Holy Grail of developmental biology. And the company faces competition not only from those working with ES cells, but also from a growing number of firms that are focusing instead on isolating stem cells from adult tissues such as blood and brain (see table below).

Because they have traveled further on a pathway of differentiation than an embryo’s cells have, such tissue-specific stem cells are believed by many to have more limited potential than ES cells or those that PPL hopes to create. Some researchers, however, are beginning to argue that these limitations would actually make tissue-specific stem cells safer than their pluripotent counterparts. University of Pennsylvania bioethicist Glenn McGee is one of the most vocal critics on this point: “The emerging truth in the lab is that pluripotent stem cells are hard to rein in. The potential that they would explode into a cancerous mass after a stem cell transplant might turn out to be the Pandora’s box of stem cell research.”

So far, the ethical debate on deriving stem cells from embryos has obscured such vital scientific questions. Perhaps advances like PPL’s will, at the very least, make discussion of these issues possible.

Companies Researching Adult Stem Cells COMPANY LOCATION STEM CELL TYPE Aastrom Biosciences Ann Arbor, Mich. Blood Neuronyx Malvern, Pa. Nerve Nexell Therapeutics Irvine, Calif. Blood Osiris Therapeutics Baltimore, Md. Connective tissue StemCells Sunnyvale, Calif. Nerve, blood

Keep Reading

Most Popular

A Roomba recorded a woman on the toilet. How did screenshots end up on Facebook?

Robot vacuum companies say your images are safe, but a sprawling global supply chain for data from our devices creates risk.

A startup says it’s begun releasing particles into the atmosphere, in an effort to tweak the climate

Make Sunsets is already attempting to earn revenue for geoengineering, a move likely to provoke widespread criticism.

10 Breakthrough Technologies 2023

Every year, we pick the 10 technologies that matter the most right now. We look for advances that will have a big impact on our lives and break down why they matter.

These exclusive satellite images show that Saudi Arabia’s sci-fi megacity is well underway

Weirdly, any recent work on The Line doesn’t show up on Google Maps. But we got the images anyway.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.